GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
Authors
Keywords
-
Journal
POSTGRADUATE MEDICINE
Volume -, Issue -, Pages 1-12
Publisher
Informa UK Limited
Online
2020-08-20
DOI
10.1080/00325481.2020.1798099
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis
- (2020) Humaira Hussein et al. DIABETES OBESITY & METABOLISM
- Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events
- (2020) Rasmus Stilling Tougaard et al. SCANDINAVIAN CARDIOVASCULAR JOURNAL
- Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
- (2020) Daisuke Yabe et al. Lancet Diabetes & Endocrinology
- Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
- (2020) Yuichiro Yamada et al. Lancet Diabetes & Endocrinology
- Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
- (2020) Stephen A. Brunton et al. POSTGRADUATE MEDICINE
- Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables
- (2019) Tricia Santos Cavaiola et al. CLINICAL THERAPEUTICS
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- (2019) V. R Aroda et al. DIABETES & METABOLISM
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- (2019) Bernard Zinman et al. Lancet Diabetes & Endocrinology
- Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis
- (2019) Lana C. Pinto et al. Scientific Reports
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area
- (2019) Manel Mata-Cases et al. CURRENT MEDICAL RESEARCH AND OPINION
- Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes
- (2019) Vivian T Thieu et al. Patient Preference and Adherence
- Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes
- (2019) Carol M. Hamersky et al. Diabetes Therapy
- Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
- (2019) Deborah Hinnen et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features
- (2019) Katherine A. Lyseng-Williamson CLINICAL DRUG INVESTIGATION
- PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
- (2019) Vanita R. Aroda et al. DIABETES CARE
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
- (2019) Richard Pratley et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
- (2019) Thomas R Pieber et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
- (2019) Bernard Zinman et al. DIABETES CARE
- Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
- (2019) Helena W. Rodbard et al. DIABETES CARE
- The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials
- (2019) Maria Ida Maiorino et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
- (2019) Ildiko Lingvay et al. Lancet Diabetes & Endocrinology
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
- (2019) DIABETES CARE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials
- (2019) Mirna Abd El Aziz et al. DIABETES OBESITY & METABOLISM
- Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months
- (2019) Fernando Moreno Obregón et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
- (2019) Michael A Nauck et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
- (2019) Marco Castellana et al. Scientific Reports
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment
- (2018) Reema Mody et al. CURRENT MEDICAL RESEARCH AND OPINION
- A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials
- (2018) Vanita R. Aroda DIABETES OBESITY & METABOLISM
- Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials
- (2018) Susan Tran et al. DIABETES OBESITY & METABOLISM
- What have we learnt from “real world” data, observational studies and meta-analyses
- (2018) Sudesna Chatterjee et al. DIABETES OBESITY & METABOLISM
- Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
- (2018) Tina Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
- (2018) Helena W Rodbard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Primary nonadherence to chronic disease medications: a meta-analysis
- (2018) Mark Lemstra et al. Patient Preference and Adherence
- Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement
- (2018) Francesco Giorgino et al. Patient Preference and Adherence
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
- (2018) Michal Witkowski et al. Diabetes Therapy
- A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
- (2018) Michal Witkowski et al. Diabetes Therapy
- The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (the Diabetes & Aging Study)
- (2018) Neda Laiteerapong et al. DIABETES CARE
- Worsening diabetic retinopathy with rapid improvement in systemic glucose control: a review
- (2018) Stephen C Bain et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis
- (2018) Ioannis Avgerinos et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
- (2018) Raffaella Gentilella et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review
- (2018) Jennifer Okemah et al. ADVANCES IN THERAPY
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
- (2018) Charlotte Granhall et al. CLINICAL PHARMACOKINETICS
- GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis
- (2018) Marco Castellana et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study
- (2018) Athena Philis-Tsimikas et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
- (2018) Stephen T. Buckley et al. Science Translational Medicine
- Discovery, characterization, and clinical development of the glucagon-like peptides
- (2017) Daniel J. Drucker et al. JOURNAL OF CLINICAL INVESTIGATION
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis
- (2017) Carol H. Wysham et al. POSTGRADUATE MEDICINE
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom
- (2017) Michael Feher et al. Diabetes Therapy
- Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
- (2017) Ginger Carls et al. Diabetes Therapy
- A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs
- (2017) Mikkel Ankarfeldt et al. Clinical Epidemiology
- Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom
- (2017) Michael Feher et al. Diabetes Therapy
- Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
- (2017) Ginger Carls et al. Diabetes Therapy
- Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
- (2017) Philip A Levin et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis
- (2016) Sonal Singh et al. DIABETES OBESITY & METABOLISM
- A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
- (2016) Mirna S. Abd El Aziz et al. DIABETES OBESITY & METABOLISM
- Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
- (2016) M. Nauck DIABETES OBESITY & METABOLISM
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
- (2016) William Polonsky et al. Patient Preference and Adherence
- Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
- (2016) Laurent Azoulay et al. BMJ-British Medical Journal
- Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
- (2016) Laurent Azoulay et al. BMJ-British Medical Journal
- Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
- (2016) Amrita Ostawal et al. Diabetes Therapy
- Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
- (2016) Amrita Ostawal et al. Diabetes Therapy
- Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study
- (2015) Erin K. Buysman et al. ADVANCES IN THERAPY
- Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
- (2015) Sanjoy K Paul et al. Cardiovascular Diabetology
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
- (2015) Donna Ryan et al. Obesity
- Type 2 diabetes mellitus
- (2015) Ralph A. DeFronzo et al. Nature Reviews Disease Primers
- Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
- (2014) Stephen S. Johnston et al. ADVANCES IN THERAPY
- Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care
- (2014) M. E. Nyeland et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people
- (2013) K. Khunti et al. DIABETES CARE
- Approaches for enhancing oral bioavailability of peptides and proteins
- (2013) Jwala Renukuntla et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
- (2011) J. J. Holst et al. DIABETES CARE
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Increasing Role of Primary Care Physicians in Caring for Patients With Type 2 Diabetes Mellitus
- (2010) Jaime A. Davidson MAYO CLINIC PROCEEDINGS
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started